Latham & Watkins advised Harmony Biosciences, while Paul Hastings LLP advised J.P. Morgan as the sole book-running manager in the offering. Harmony Biosciences Holdings, Inc. (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Dorsey & Whitney advised Rezolute, while Paul Hastings advised Jefferies and Cantor as joint book-running managers in the offering. Rezolute, Inc. (Nasdaq: RZLT) completed its underwritten...
You must be a Standard 1 Year member to access this content.
Thompson Hine advised Vaxart, while Paul Hastings LLP advised Oppenheimer & Co. as the sole bookrunner in the offering. Vaxart, Inc. (Nasdaq: VXRT) announced an underwritten...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell advised ProKidney, while Paul Hastings advised Jefferies, J.P. Morgan, and Guggenheim Securities, as joint book-running managers, in the transaction. ProKidney Corp. (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Monte Rosa Therapeutics, while Paul Hastings advised TD Cowen and Wedbush PacGrow, as joint book-running managers, in the offering. Monte Rosa Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Chardan Capital Markets and Invest Securities as joint global coordinators and bookrunners in the transaction. GenSight Biologics executed its private placement (PIPE)....
You must be a Standard 1 Year member to access this content.
Cooley advised INOVIO Pharmaceuticals, while Paul Hastings LLP advised Oppenheimer & Co. and Citizens JMP as joint book running managers in the offering. INOVIO executed an...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised J.P. Morgan Securities LLC as the exclusive placement agent in the transaction. Leap Therapeutics, Inc. (Nasdaq:LPTX) has entered into a securities purchase agreement with...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised BofA Securities as the sole placement agent in the transaction. Century entered into a securities purchase agreement with a select group of...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised NervGen Pharma Corp. in the transaction. NervGen Pharma Corp. closed its public offering including the full exercise of the underwriters’ over-allotment option...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Leerink Partners and Stifel as joint bookrunning managers in the offering. Evolus, Inc. (Nasdaq: EOLS) announced the pricing of its underwritten offering...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Piper Sandler and Co. as lead placement agent, and Oppenheimer & Co. as placement agent in the transaction. Skye Bioscience, Inc. (OTCQB:...
You must be a Standard 1 Year member to access this content.
